Four seronegative adult boars were intranasally inoculated with porcine reproductive and respiratory syndrome virus (PRRSV) isolate VR-2332. Serum and semen were collected 2-3 times weekly for over 100 days postinoculation (DPI). Serum samples were assayed for PRRSV by virus isolation (VI) and a polymerase chain reaction (PCR) and screened for antibodies to PRRSV using the indirect fluorescent antibody (IFA) and virus neutralization (VN) tests. Semen was assayed for PRRSV RNA by PCR. Virus or viral RNA was detected in the serum of all boars within 1 DPI by VI and/or PCR. However, VI results indicated that viremia was transient and occurred from 1 to 9 DPI. Viral RNA was detected in serum from 1 to 31 DPI. In the acute stage of the infection, PRRSV RNA was detected in serum by PCR prior to the presence of viral RNA in semen. The PRRSV RNA was detected in semen as early as 3 DPI and persisted for 25 DPI in 2 of the boars and 56 and 92 DPI in the remaining 2 boars. Detection of PRRSV RNA in semen occurred 2-8 and 28-35 days prior to the detection of antibodies by IFA and VN, respectively. PRRSV was isolated from the bulbourethral gland of the boar that shed viral RNA in semen for 92 DPI. These results suggest that PRRSV RNA can be detected by PCR in boar serum and semen, and may persist for variable periods of time. Viremia and the serologic status of the boar are not adequate indicators of when PRRSV or PRRSV RNA is being shed in the semen. Preliminary findings also indicated that neither shipping stress nor reinoculation with homologous PRRSV resulted in viremia or viral RNA shedding in semen.

Bluetongue virus (BTV) and epizootic hemorrhagic disease virus (EHDV) are arthropod-transmitted viruses in the genus Orbivirus of the family Reoviridae. These viruses infect a variety of domestic and wild ruminant hosts, although the susceptibility to clinical disease associated with BTV or EHDV infection varies greatly among host species, as well as between individuals of the same species. Since their initial detection in North America during the 1950s, these viruses have circulated in endemic and epidemic patterns, with occasional incursions to more northern latitudes. In recent years, changes in the pattern of BTV and EHDV infection and disease have forced the scientific community to revisit some fundamental areas related to the epidemiology of these diseases, specifically in relation to virus-vector-host interactions and environmental factors that have potentially enabled the observed changes. The aim of this review is to identify research and surveillance gaps that obscure our understanding of BT and EHD in North America.

Forty-five Holstein calves were fed milk replacers containing either antibiotics [MRA (oxytetracycline at 138 mg/kg and neomycin at 276 mg/kg), n = 22)] or Enteroguard [MRE, a blend of fructooligosaccharides, allicin, and gut-active microbes at (129 mg/kg, n = 23)] from birth to 5 wk of age to compare effects on average daily gain and on incidence of scours. Performance was evaluated by measuring weight gain, feed efficiency, and fecal scores. The overall body weight gains and severity of scours were not different between treatments, nor were there differences in starter intake or mean body weight gain. During wk 2, the average gain of calves fed MRA was less than that of calves fed MRE (0.07 vs. 0.09 kg/d, P = 0.09), and greater during wk 5 (0.62 vs. 0.51 kg/d, P < 0.01); however, total gain for calves fed MRE was not different from calves fed MRA. Likewise, average feed efficiencies (gain/dry matter intake) were not different. Severity of scours, as measured by fecal scores, and concentrations of serum proteins, an indirect measure of immunoglobulins, were similar for calves fed MRA and MRE. The results suggest that antibiotics in milk replacers can be replaced with compounds such as fructooligosaccharides, probiotics, and allicin to obtain similar calf performance.